Holistic Financial Partners Vertex Pharmaceuticals Inc Transaction History

Holistic Financial Partners

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 12, 2021	SELL	$181.39 - $202.99 $820,064 - $917,717	-4,521 Closed	0 $0
Q1 2021 May 11, 2021	BUY	$207.02 - $241.31 $39,333 - $45,848	190 Added 4.39%	4,521 $972,000
Q4 2020 Feb 10, 2021	BUY	$207.01 - $276.09 $15,318 - $20,430	74 Added 1.74%	4,331 $1.02 Million
Q3 2020 Nov 13, 2020	BUY	$255.65 - $303.1 $10,481 - $12,427	41 Added 0.97%	4,257 $1.16 Million
Q1 2020 May 05, 2020	BUY	$199.77 - $247.81 $67,722 - $84,007	339 Added 8.74%	4,216 $1 Million
Q3 2019 Nov 07, 2019	BUY	$166.23 - $187.09 $644,473 - $725,347	3,877 New	3,877 $657,000
Q2 2019 Aug 07, 2019	SELL	$164.61 - $190.37 $641,485 - $741,871	-3,897 Closed	0 $0
Q3 2018 Nov 05, 2018	BUY	$167.73 - $192.74 $653,643 - $751,107	3,897 New	3,897 $751,000
Q2 2018 Aug 14, 2018	SELL	$145.72 - $169.96 $570,785 - $665,733	-3,917 Closed	0 $0
Q1 2018 May 14, 2018	SELL	$151.6 - $177.13 $17,434 - $20,369	-115 Reduced 2.85%	3,917 $638,000
Q4 2017 Feb 09, 2018	BUY	$137.28 - $155.55 $553,512 - $627,177	4,032	4,032 $604,000

1,721

227M

1.21M

1.56M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $127B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Holistic Financial Partners, based on Form 13F filings with the SEC.

Stay updated on Holistic Financial Partners with notifications on news.